Synonyms: | |
Status: | Approved (2019) |
Entry Type: | Small molecule |
Molecule Category: | Parent |
ATC: | N07XX11 |
UNII: | 4BC83L4PIY |
InChI Key | NNACHAUCXXVJSP-UHFFFAOYSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C17H26ClNO |
Molecular Weight | 295.85 |
AlogP | 4.17 |
Hydrogen Bond Acceptor | 2.0 |
Hydrogen Bond Donor | 0.0 |
Number of Rotational Bond | 8.0 |
Polar Surface Area | 12.47 |
Molecular species | BASE |
Aromatic Rings | 1.0 |
Heavy Atoms | 20.0 |
Primary Target | |
---|---|
H3 receptor |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Enzyme
Hydrolase
|
- | 8400-8420 | - | - | 3 | |
Enzyme
Oxidoreductase
|
- | - | - | - | 2 | |
Ion channel
Voltage-gated ion channel
Potassium channels
Voltage-gated potassium channel
|
- | 1700 | - | - | - | |
Membrane receptor
Family A G protein-coupled receptor
Small molecule receptor (family A GPCR)
Monoamine receptor
Histamine receptor
|
2 | 12 | 6 | 0-30 | - |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Narcolepsy | 3 | D009290 | ClinicalTrials |
Parkinson Disease | 3 | D010300 | ClinicalTrials |
Narcolepsy | 3 | D009290 | ClinicalTrials |
Prader-Willi Syndrome | 2 | D011218 | ClinicalTrials |
Schizophrenia | 2 | D012559 | ClinicalTrials |
Alcoholism | 2 | D000437 | ClinicalTrials |
Kidney Diseases | 1 | D007674 | ClinicalTrials |
Substance-Related Disorders | 1 | D019966 | ClinicalTrials |
Resources | Reference |
---|---|
CAS NUMBER | 362665-56-3 |
ChEBI | 134709 |
ChEMBL | CHEMBL462605 |
DrugBank | DB11642 |
DrugCentral | 5048 |
FDA SRS | 4BC83L4PIY |
Guide to Pharmacology | 8924 |
PubChem | 9948102 |
SureChEMBL | SCHEMBL117648 |
ZINC | ZINC000034045468 |